{"id":"NCT00838903","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","officialTitle":"A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2012-01","completion":"2013-04","firstPosted":"2009-02-09","resultsPosted":"2014-05-16","lastUpdate":"2017-01-09"},"enrollment":1049,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"BIOLOGICAL","name":"albiglutide","otherNames":[]},{"type":"DRUG","name":"sitagliptin","otherNames":[]},{"type":"DRUG","name":"glimepiride","otherNames":[]},{"type":"DRUG","name":"metformin","otherNames":[]},{"type":"BIOLOGICAL","name":"placebo albiglutide","otherNames":[]},{"type":"DRUG","name":"placebo sitagliptin","otherNames":[]},{"type":"DRUG","name":"placebo glimepiride","otherNames":[]}],"arms":[{"label":"albiglutide + metformin","type":"EXPERIMENTAL"},{"label":"sitagliptin + metformin","type":"ACTIVE_COMPARATOR"},{"label":"glimepiride + metformin","type":"ACTIVE_COMPARATOR"},{"label":"metformin + placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.","primaryOutcome":{"measure":"Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104","timeFrame":"Baseline and Week 104","effectByArm":[{"arm":"Placebo Plus Metformin","deltaMin":0.27,"sd":0.113},{"arm":"Sitagliptin 100 mg Plus Metformin","deltaMin":-0.28,"sd":0.065},{"arm":"Glimepiride 2 mg Plus Metformin","deltaMin":-0.36,"sd":0.064},{"arm":"Albiglutide 30 mg Plus Metformin","deltaMin":-0.63,"sd":0.065}],"pValues":[{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"0.0001"},{"comp":"OG002 vs OG003","p":"0.0033"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":386,"countries":["United States","Albania","Germany","Hong Kong","Mexico","Peru","Philippines","Russia","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["28683300"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":101},"commonTop":["Hypoglycaemia","Upper respiratory tract infection","Diarrhoea","Urinary tract infection","Hypertension"]}}